Category Archives: News

AB Science announces the successful completion of a EUR 3.2 million private placement

29/04/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors

AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors

27/04/2026 – AB Science announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt and the 12-month deferral of repayment of a loan subscribed with the EIB

New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

20/04/2026 – AB Science announced the publication of a new article on the preprint platform medRxiv, evaluating long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study

Update on clinical development program

16/04/2026 – AB Science provides an update on its clinical development program

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS)

FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®

09/02/2026 – AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

29/01/2026 – AB Science announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent relating to methods of treating metastatic castrate resistant prostate cancer (mCRPC)

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

21/01/2026 – AB Science today announced that the Japanese Patent Office has formally granted a patent for methods of treating progressive multiple sclerosis (MS) with its lead compound masitinib

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

07/01/2026 – AB Science today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in patients with acute myeloid leukemia

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040

22/12/2025 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using its lead compound masitinib, based on preclinical data